Understood
This website is using cookies. More details
NEWS

BioMedomics COVID-19 IgM/IgG Rapid test

BioMedomics has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection...

OXFORD BIOSYSTEMS and BIOMEDOMICS™ sign exclusive distribution agreement for UK

Founded in 2007, BioMedomics is a privately-held clinical diagnostics company in North Carolina, USA. Their researchers combine biology, biochemistry and...

Orion Diagnostica announce a change to their company name!

Orion Diagnostica are manufacturers of the UniQ product range, including the PIIINP RIA kit, and the microbiology products Hygicult, Uricult, Easicult...

BioMedomics COVID-19 IgM/IgG Rapid test

BioMedomics COVID-19 IgM/IgG Rapid test

BioMedomics Inc (USA) has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. This test detects both IgM/IgG antibodies in human finger-prick or venous blood samples. It can also be used to test human serum or plasma samples.

This CE marked test can be used as a point of care test for rapid screening to identify individuals who have been previously exposed to the virus. Studies suggest that a significant percentage of patients show no clinical symptoms of the virus, thus screening patients is vitally important in the fight against this global threat.


This kit is registered with the MHRA and sold in the UK

For Professional Use only.


BioMedomics COVID-19 IgM/IgG Rapid test

How it works

BioMedomics COVID-19 IgM/IgG Rapid Test - How it Works, the 4-steps finger prick

Results

BioMedomics COVID-19 IgM/IgG Rapid Test Results

Negative Result: If only the quality control line (C) appears and G and M are not visible, then the result is negative.

Positive Result, M only: If both C and M appear, then the result is positive for the IgM antibody.

Positive Result, G only: If both C and G appear, then the result is positive for the IgG antibody.

Positive Result, G and M: If C and both G and M appear, then the result is positive for both the IgG and IgM antibodies

Validation

In order to test the detection sensitivity and specificity of the COVID-19 IgG-IgM combined antibody test, blood samples were collected from COVID-19 patients from multiple hospitals and Chinese CDC laboratories. The tests were done separately at each site. A total of 525 cases were tested: 397 (positive) clinically confirmed (including PCR test) SARS-CoV-2-infected patients and 128 non- SARS-CoV-2-infected patients (128 negative). The testing results of vein blood without viral inactivation were summarized in the Table 1. Of the 397 blood samples from SARS-CoV-2-infected patients, 352 tested positive, resulting in a sensitivity of 88.66%. Twelve of the blood samples from the 128 non-SARS-CoV-2 infection patients tested positive, generating a specificity of 90.63%.

Contact us for additional information and availability

Oxford Biosystems

184B Park Drive

Milton Park

Abingdon

Oxon

OX14 4SE

Oxford Biosystems has pledged to be an Antibiotic Guardian

Members of:

BIVDA Member 2019 IBMS member